Treatment of glaucoma in patients with dry eye syndrome;Le traitement du glaucome chez les patients atteints de syndrome sec oculaire

Journal Francais d'Ophtalmologie

Volumn 33, Issue 4, 2010, Pages 285-290

  Labbe A ^a,b,c   Baudouin, C ^a,b,c  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b INSTITUT DE LA VISION   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Dry eye; Glaucoma; Ocular hypertension; Treatment

Indexed keywords

EYE DROPS;

ARTICLE; DRUG EFFECT; DRY EYE; EYE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; PATHOLOGY; TRABECULECTOMY;

DRY EYE SYNDROMES; EYE; GLAUCOMA; HUMANS; LASER THERAPY; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; TRABECULECTOMY;

EID: 77953135450     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2010.02.006     Document Type: Article

References (31)

1. Schaumberg D.A., Sullivan D.A., Buring J.E., and Dana M.R. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 136 (2003) 318-326
2. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 86 (2008) 716-726
3. Asbell P.A., and Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocul Surf 3 (2005) 27-40
4. Leung E.W., Medeiros F.A., and Weinreb R.N. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17 (2008) 350-355
5. Jaenen N., Baudouin C., Pouliquen P., Manni G., Figueiredo A., and Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17 (2007) 341-349
6. Anders N., and Wollensak J. [Ocular pseudopemphigoid after topical drug administration]. Klin Monbl Augenheilkd 205 (1994) 61-64
7. Schwab I.R., Linberg J.V., Gioia V.M., Benson W.H., and Chao G.M. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 99 (1992) 197-202
8. Schwartz G.F., and Quigley H.A. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 53 Suppl1 (2008) S57-S68
9. Chawla A., McGalliard J.N., and Batterbury M. Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand 85 (2007) 464
10. Nordmann J.P., Auzanneau N., Ricard S., and Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 1 (2003) 75
11. Labbe A., Khammari C., and Baudouin C. Modulation de la cicatrisation dans la chirurgie du glaucome. J Fr Ophtalmol 30 (2007) 631-646
12. European-Glaucoma-Society, ed. Terminology and guidelines for glaucoma. Savona, Italie, 2003.
13. Broadway D.C., Grierson I., O'Brien C., and Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 112 (1994) 1446-1454
14. Broadway D.C., Grierson I., O'Brien C., and Hitchings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 112 (1994) 1437-1445
15. Gasset A.R., Ishii Y., Kaufman H.E., and Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 78 (1974) 98-105
16. Burstein N.L. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 19 (1980) 308-313
17. Tripathi B.J., Tripathi R.C., and Kolli S.P. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 9 (1992) 361-375
18. Pisella P.J., Pouliquen P., and Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 86 (2002) 418-423
19. Lachkar Y. Intérêt des combinaisons fixes. J Fr Ophtalmol 31 2 (2008) S85-S89
20. Pham H., Mansberger S., Brandt J.D., Damji K., Ramulu P.Y., and Parrish R.K. Argon laser trabeculoplasty versus selective laser trabeculoplasty. Surv Ophthalmol 53 (2008) 641-646
21. Stein J.D., and Challa P. Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty. Curr Opin Ophthalmol 18 (2007) 140-145
22. Hodge W.G., Damji K.F., Rock W., Buhrmann R., Bovell A.M., and Pan Y. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol 89 (2005) 1157-1160
23. Juzych M.S., Chopra V., Banitt M.R., Hughes B.A., Kim C., Goulas M.T., et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology 111 (2004) 1853-1859
24. Lai J.S., Chua J.K., Tham C.C., and Lam D.S. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol 32 (2004) 368-372
25. McIlraith I., Strasfeld M., Colev G., and Hutnik C.M. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma 15 (2006) 124-130
26. Nagar M., Ogunyomade A., O'Brart D.P., Howes F., and Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol 89 (2005) 1413-1417
27. Broadway D.C., Grierson I., Sturmer J., and Hitchings R.A. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol 114 (1996) 262-267
28. ® et la pilocarpine doivent-ils encore être prescrits ?. J Fr Ophtalmol 30 3 (2007) S72-S73
29. Baudouin C. Un nouveau schéma pour mieux comprendre les maladies de la surface oculaire. J Fr Ophtalmol 30 (2007) 239-246
30. Dursun D., Kim M.C., Solomon A., and Pflugfelder S.C. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol 132 (2001) 8-13
31. Foulks G.N. Pharmacological management of dry eye in the elderly patient. Drugs Aging 25 (2008) 105-118